# Clostridioides difficile Infection: Current Management

## Overview

Clostridioides difficile infection (CDI) is the most common healthcare-associated infection in the United States, with a spectrum ranging from mild diarrhea to fulminant colitis with toxic megacolon. Recurrence represents a major clinical challenge, occurring in 15-30% after the initial episode and increasing with each subsequent recurrence. The treatment landscape has evolved significantly and now includes fidaxomicin, fecal microbiota transplantation (FMT), and FDA-approved live biotherapeutic products.

## Pathophysiology and Risk Factors

### Mechanism of Disease

Disruption of the normal colonic microbiome, typically by antibiotics, allows C. difficile spore germination. Toxin A (enterotoxin) and Toxin B (cytotoxin) cause mucosal inflammation and damage. Binary toxin (CDT) is produced by hypervirulent strains such as NAP1/BI/027 and is associated with more severe disease. Pseudomembrane formation, appearing as yellow-white plaques on the colonic mucosa, is the histologic hallmark.

### Key Risk Factors

Antibiotic exposure is the most important risk factor, particularly fluoroquinolones, clindamycin, broad-spectrum cephalosporins, and carbapenems. Age above 65, hospitalization or long-term care facility residence, proton pump inhibitor use (a modest and debated association), immunosuppression from chemotherapy or organ transplant, inflammatory bowel disease (an independent risk factor), and prior CDI episodes all increase susceptibility.

<image>Pathogenesis of Clostridioides difficile infection showing antibiotic-mediated microbiome disruption, spore germination, toxin production, and mucosal damage</image>

## Diagnosis

### Clinical Presentation

The hallmark symptom is watery diarrhea, defined as three or more unformed stools in 24 hours. Abdominal pain and cramping, low-grade fever, and leukocytosis are common accompanying findings. Severe disease presents with profuse diarrhea, abdominal distension, white blood cell count of 15,000 or higher, and creatinine rise to 1.5 times baseline or greater. Fulminant disease manifests with hypotension, shock, and ileus, which may paradoxically result in decreased stool output and lead to megacolon.

### Diagnostic Testing

The preferred approach endorsed by IDSA/SHEA is a two-step algorithm: Step 1 uses GDH (glutamate dehydrogenase) EIA or NAAT (PCR) as a screening test, followed by Step 2 using Toxin A/B EIA for confirmation. NAAT (PCR) alone is highly sensitive but detects colonization in addition to true infection, requiring correlation with clinical symptoms. Toxin EIA alone is specific but less sensitive. The key principle is to test only patients with clinically significant diarrhea; formed stool should not be tested, and "test of cure" after treatment should never be performed.

### Severity Classification (IDSA/SHEA 2021)

| CDI Severity | Criteria | First-Line Treatment |
|-------------|----------|---------------------|
| Non-severe | WBC ≤15,000 AND Cr <1.5 mg/dL | Fidaxomicin 200 mg BID x 10 days (or vancomycin 125 mg QID x 10 days) |
| Severe | WBC ≥15,000 OR Cr ≥1.5x baseline | Fidaxomicin or vancomycin (same doses) |
| Fulminant | Hypotension, shock, ileus, or megacolon | Vancomycin 500 mg PO/NG QID + metronidazole 500 mg IV Q8H ± rectal vancomycin |

Non-severe CDI is defined by a white blood cell count of 15,000 or less and creatinine below 1.5 mg/dL. Severe CDI is defined by white blood cell count of 15,000 or higher or creatinine at 1.5 times baseline or greater. Fulminant CDI involves hypotension, shock, ileus, or megacolon.

<image>Diagnostic algorithm for Clostridioides difficile infection showing two-step testing approach with GDH/NAAT screening followed by toxin EIA confirmation</image>

## Treatment

### Initial Episode

For non-severe CDI, fidaxomicin 200 mg orally twice daily for 10 days is preferred. Vancomycin 125 mg orally four times daily for 10 days is an alternative. Metronidazole 500 mg orally three times daily for 10 days is now a distant third-line option, used only when vancomycin and fidaxomicin are unavailable. For severe CDI, the same fidaxomicin or vancomycin regimens apply. For fulminant CDI, vancomycin 500 mg orally or via nasogastric tube four times daily is combined with metronidazole 500 mg IV every 8 hours. If ileus is present, vancomycin rectal enemas (500 mg in 100 mL normal saline every 6 hours) are added. Early surgical consultation for colectomy is essential in fulminant cases.

### Recurrent CDI

For a first recurrence, fidaxomicin is preferred, either as a standard course or as an extended-pulsed regimen (200 mg twice daily for 5 days, then 200 mg once daily on alternate days for 20 days). A vancomycin taper and pulse is used if fidaxomicin is not available. For second or subsequent recurrences, fecal microbiota transplantation after a course of standard antibiotic therapy is an established option. FDA-approved live biotherapeutic products include fecal microbiota, live-jslm (Rebyota) given as a single rectal administration, and fecal microbiota spores, live-brpk (Vowst) given as an oral capsule course. Bezlotoxumab, an anti-toxin B monoclonal antibody, serves as adjunctive therapy to reduce recurrence risk.

### Supportive Measures

Offending antibiotics should be discontinued if possible. Antiperistaltic agents such as loperamide must be avoided due to the risk of toxic megacolon. Contact precautions with soap and water hand hygiene are required because alcohol-based sanitizers do not kill spores. Antibiotic stewardship programs help prevent new cases.

<image>Treatment algorithm for initial and recurrent Clostridioides difficile infection including standard therapy, fidaxomicin pulsed regimens, and microbiome restoration therapies</image>

## Infection Prevention

Contact precautions should be maintained for the duration of diarrhea. Soap and water hand hygiene (not alcohol-based hand rub) is essential. Environmental cleaning requires sporicidal agents (bleach-based). Antimicrobial stewardship programs reduce unnecessary antibiotic exposure. Probiotics such as Saccharomyces boulardii and Lactobacillus have weak evidence for primary prevention and are not routinely recommended.

## Clinical Pearls

A leukemoid reaction (white blood cell count above 40,000) in CDI is a marker of severe disease and high mortality. Ileus in fulminant CDI can cause a paradoxical decrease in diarrhea, and clinicians should not interpret improvement in stool output as clinical improvement without corroborating data. Lactate above 5 mmol/L and age above 65 in fulminant CDI are associated with mortality exceeding 50%, prompting early surgical evaluation. Test of cure is never indicated because patients can shed the organism for weeks after successful treatment. Community-acquired CDI is increasing, including in patients without traditional risk factors such as younger individuals without recent antibiotic exposure.

<image>Endoscopic image of pseudomembranous colitis showing characteristic yellow-white plaques on inflamed colonic mucosa</image>

## References

- Johnson S, et al. Clinical Practice Guideline by IDSA and SHEA: 2021 Focused Update on CDI in Adults. Clin Infect Dis. 2021;73(5):e1029-e1044.
- Kelly CP, LaMont JT. Clostridium difficile -- More Difficult Than Ever. N Engl J Med. 2008;359:1932-1940.
- Feuerstadt P, et al. SER-109, an Oral Microbiome Therapy for Recurrent CDI. N Engl J Med. 2022;386:220-229.
- Wilcox MH, et al. Bezlotoxumab for Prevention of Recurrent CDI. N Engl J Med. 2017;376:305-317.
- Guery B, et al. Extended-pulsed fidaxomicin vs vancomycin for CDI: EXTEND RCT. Lancet Infect Dis. 2018;18(3):296-307.